Rachel King Biography and Net Worth

Director of Novavax

Mrs. King joined the Novavax board of directors in 2018. She is the cofounder and chief executive officer of GlycoMimetics, Inc., a clinical-stage biotechnology company. Before founding GlycoMimetics, Inc. in 2003, Mrs. King was an executive in residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. Mrs. King joined NEA after serving as a senior vice president at Novartis Corporation. Before Novartis, Mrs. King spent 10 years with Genetic Therapy, Inc. (GTI), through the company’s early stages, initial public offering, and eventual sale to Novartis, after which she ran GTI as a wholly owned subsidiary of Novartis. Previously, Mrs. King worked at ALZA Corporation and Bain and Company. Mrs. King currently serves on the executive committee of the Biotechnology Innovation Organization (BIO). She also sits on the board of directors of the University of Maryland BioPark. Mrs. King received a bachelors of arts degree from Dartmouth College and a master’s degree in business administration from Harvard Business School.

What is Rachel K. King's net worth?: The estimated net worth of Rachel K. King is at least $103,390.00 as of December 13th, 2024. Ms. King owns 14,770 shares of Novavax stock worth more than $103,390 as of March 30th. This net worth evaluation does not reflect any other assets that Ms. King may own. Learn More about Rachel K. King's net worth.
How do I contact Rachel K. King?: The corporate mailing address for Ms. King and other Novavax executives is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. Novavax can also be reached via phone at (240) 268-2000 and via email at ir@novavax.com. Learn More on Rachel K. King's contact information.
Has Rachel K. King been buying or selling shares of Novavax?: Rachel K. King has not been actively trading shares of Novavax during the past quarter. Most recently, Rachel K. King sold 4,150 shares of the business's stock in a transaction on Friday, December 13th. The shares were sold at an average price of $9.02, for a transaction totalling $37,433.00. Following the completion of the sale, the director now directly owns 14,770 shares of the company's stock, valued at $133,225.40. Learn More on Rachel K. King's trading history.
Who are Novavax's active insiders?: Novavax's insider roster includes Stanley Erck (CEO), Gary Evans (Director), Gregory Glenn (Insider), John Herrmann, II (President, CEO & Director), Rachel King (Director), Michael McManus, Jr. (Director), David Mott (Director), John Trizzino (CFO), and James Young (Director). Learn More on Novavax's active insiders.
Are insiders buying or selling shares of Novavax?: During the last twelve months, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 76,462 shares worth more than $985,852.80. The most recent insider tranaction occured on December, 31st when Director James F Young sold 5,400 shares worth more than $43,200.00. Insiders at Novavax own 1.0% of the company. Learn More about insider trades at Novavax.
Information on this page was last updated on 12/31/2024.

Rachel K. King Insider Trading History at Novavax

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/13/2024	Sell	4,150	$9.02	$37,433.00	14,770
5/19/2021	Buy	700	$139.64	$97,748.00	2,800
3/27/2019	Buy	86,000	$0.53	$45,580.00	42,000

Rachel K. King Buying and Selling Activity at Novavax

Novavax Company Overview

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $7.00

$6.93

$7.29

50 Day Range

MA: $8.13

$7.00

$9.55

2 Week Range

Now: $7.00

$3.81

$23.86

Volume

2,783,556 shs

Average Volume

8,038,761 shs

Market Capitalization

$1.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.92